Protocolo de tratamiento de la disfunción del tracto urinario inferior en la esclerosis múltiple y trastornos relacionados

  1. Alberte Woodward, M. 1
  2. Rey Rey, J. 2
  3. Prieto González, J.M.Ó 1
  1. 1 Servicios de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
  2. 2 Servicios de Urología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2023

Título del ejemplar: Enfermedades del sistema nervioso (IX): Enfermedades desmielinizantes

Serie: 13

Número: 78

Páginas: 4646-4648

Tipo: Artículo

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Lower urinary tract dysfunction (LUTD) affects between a third and the majority of patients with multiple sclerosis, its prevalence increasing with the duration of the disease and causing a great impact on quality of life. LUTD is classified into filling symptoms, voiding symptoms, or mixed symptoms. The scenario of simultaneous contraction of the detrusor and bladder sphincter is called bladder detrusor sphincter dyssynergia and requires periodic ultrasound and renal function monitoring, due to the risk of kidney impairment caused by a retrograde increase in pressure. Filling symptoms are treated with hygienic-dietary measures, antimuscarinics, mirabegron, desmopressin, botulinum toxin or neuromodulation. Symptoms of voiding (postvoid residue greater than 100 mL) are treated with intermittent self-catheterization or, less commonly, indwelling bladder or suprapubic catheterization.

Referencias bibliográficas

  • Panicker JN, Sakakibara R. Lower urinary tract and bowel dysfunction in neurologic disease. Continuum (Minneap Minn). 2020;26(1):178-99.
  • Spain R. Approach to symptom management in multiple sclerosis with a focus on wellness. Continuum (Minneap Minn). 2022;28(4):1052-82.
  • Tobin WO. Management of multiple sclerosis symptoms and comorbidities. Continuum (Minneap Minn). 2019;25(3):753-72.